UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 15, 2015
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
| Nevada | 000-53605 | 26-1265381 | ||
| (State
or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S.
Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | 48307 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 248-651-6568
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 7 – Regulation FD Disclosure
| Item 7.01 | Regulation FD Disclosure |
On December 15, 2015, we issued a press release concerning the appointment of James Brooks to the new position of senior vice president of business development. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Press release, dated December 15, 2015 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OptimizeRx Corporation | |
| Date: December 15, 2015 | /s/ Doug Baker |
| Doug Baker Chief Financial Officer |
3
Exhibit 99.1
OptimizeRx Corporation Appoints James Brooks as SVP of Business Development
Dec 15, 2015
OTC Disclosure & News Service
OptimizeRx Corporation Appoints James Brooks as SVP of Business Development
ROCHESTER, MI--(Marketwired - December 15, 2015) - OptimizeRx Corp. (OTCQB: OPRX), a software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-care services, has appointed James Brooks to the new position of senior vice president of business development, effective January 4, 2016.
"James' extensive executive sales and marketing experience, particularly his track record of growing the topline and sales leadership at FORTUNE 500 and electronic health record companies, makes him a great fit with OptimizeRx," said David Harrell, the company's CEO. "James will champion our EHR business through development of new relationships with other EHR providers and patient platforms. He brings to us numerous relationships within large EHRs that can be leveraged to integrate OptimizeRx savings and support to reach more doctors and patients."
The company recently announced an expansion of its relationship with Allscripts, who will work with OptimizeRx exclusively to manage their patient savings across all of their electronic health record (EHR) platforms, including their largest platform, Touchworks, which will be integrated in 2016.
OptimizeRx's network is the largest of its kind, with more than 350 leading EHRs engaging more healthcare providers at the 'point-of-prescribe' than any other network to provide sample vouchers, copay savings and other patient support that is automated for doctors and pharmacists.
James Brooks Bio
Brooks brings more than 20 years of experience in sales & marketing, including sales force development, sales management, and organizational leadership processes within the Electronic Health Record (EHR) and Healthcare Technology sector.
Prior to joining OptimizeRx, he served as chief revenue officer at iCare, an enterprise cloud EHR and revenue cycle management system vendor.
Prior to iCare, Brooks served as executive vice president at Modernizing Medicine, a leading provider of EHR systems focused on the dermatology, ophthalmology, plastic, and orthopedic marketplace. While at Modernizing Medicine, he was responsible for developing and managing a world-class sales and marketing team and grew the business into one of the largest specialty EHRs.
Brooks additionally served as vice president of the enterprise sales and radiology division at Sage North America, a provider of information systems with a focus on healthcare with $300 million in annual revenue and 1,200 staff members.
Earlier in his career, he served as senior sales executive and enterprise vice president of clinical sales at McKesson, a FORTUNE 500 company delivering healthcare services and information technology.
Brooks holds a Bachelor of Arts in Economics and Speech Communication from St. Cloud State University in Minnesota.
About
OptimizeRx Corporation
OptimizeRx Corporation (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and
comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to
expand awareness, access and adherence to their medications.
The company's core product, SampleMD™, replaces drug samples with electronic trial vouchers and copay coupon savings, which are added to an e-Prescription and electronically sent to the pharmacy. SampleMD is integrated within leading Electronic Health Record (EHR) platforms, including Allscripts, Quest Diagnostics, Practice Fusion and over 350 other EHRs.
OptimizeRx's proprietary technology reaches over 250,000 healthcare providers. In turn, the company promotes patient savings and support from the world's largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, visit www.optimizerxcorp.com.
Important
Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as
amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make
an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements,
which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties
to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition
and other material risks.
Company
Contact:
OptimizeRx
Doug Baker
Email contact
248-651-6568 x807
Investor Relations Contact:
Liolios Group
Ron Both
Senior Managing Director
Email contact
949-574-3860
Copyright © 2015 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.